Krystal Biotech Inc (KRYS)vsMerck & Company Inc (MRK)
KRYS
Krystal Biotech Inc
$305.71
+3.04%
HEALTHCARE · Cap: $8.75B
MRK
Merck & Company Inc
$111.38
-0.82%
HEALTHCARE · Cap: $277.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15660% more annual revenue ($65.77B vs $417.30M). KRYS leads profitability with a 53.9% profit margin vs 13.6%. MRK trades at a lower P/E of 31.6x. KRYS earns a higher WallStSmart Score of 65/100 (C+).
KRYS
Buy65
out of 100
Grade: C+
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KRYS.
Margin of Safety
-14.9%
Fair Value
$97.76
Current Price
$111.38
$13.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Strong operational efficiency at 46.1%
Revenue surging 31.9% year-over-year
Earnings expanding 52.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 53.9% and operating margin at 46.1%. Revenue growth of 31.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KRYS profiles as a growth stock while MRK is a value play — different risk/reward profiles.
KRYS carries more volatility with a beta of 0.49 — expect wider price swings.
KRYS is growing revenue faster at 31.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (65/100 vs 50/100), backed by strong 53.9% margins and 31.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?